ALXO — ALX ONCOLOGY HLDGS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ALXO?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 3 tracked investors who changed their ALXO position last quarter, 0 bought and 3 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).
- +2 tracked investors reported holding ALXO at their latest filing
- +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
- −3 tracked investors reduced or exited last quarter (2 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.
About ALX ONCOLOGY HLDGS INC (ALXO)
ALX ONCOLOGY HLDGS INC (ALXO) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $9M. Across recent filings, tracked investors recorded 5 new positions, 5 increased, 9 reduced, and 4 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ALXO
How many top investors track ALXO
Only 2 tracked investors report this position.
ALXO Ownership Composition
How ALX ONCOLOGY HLDGS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting ALXO
2 tracked investors have since exited this position — listed separately below.
- Izzy EnglanderJun 30, 2026Millennium ManagementShares1.5MValue$3.2M% Portfolio0.00%
- Ken GriffinJun 30, 2026Citadel AdvisorsShares36.2KValue$74.9K% Portfolio0.00%
Previously held ALXO
These investors reported ALXO in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 41.1K | $82.4K | Mar 31, 2026 |
| Paul Tudor Jones | Tudor Investment Corp | 10.1K | $60.9K | Jun 30, 2024 |
Recent activity
- Increased$3.6M(37.60%)Nov 14, 2024
- Increased$3.8M(12.57%)Feb 14, 2025
- Reduced$588.2K(-58.12%)May 15, 2025
- Reduced$204.5K(-47.82%)Aug 14, 2025
- Increased$3.7M(24.06%)Feb 17, 2026
- Reduced$4M(-39.82%)May 15, 2026
- Reduced$3.2M(-22.38%)Aug 14, 2026
- Reduced$143.1K(-43.82%)Nov 14, 2024
- Reduced$39.3K(-32.46%)May 15, 2025
- Increased$27.2K(3.95%)Aug 14, 2025
- Reduced$105.2K(-12.21%)Nov 14, 2025
- Sold$0(-100.00%)Feb 17, 2026
- Reduced$74.9K(-2.16%)Aug 14, 2026
- Sold$0(-100.00%)Nov 14, 2024
- New$22.8KFeb 17, 2026
- Increased$82.4K(103.27%)May 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
- Reduced$60.9K(-50.11%)Aug 14, 2024
- Sold$0(-100.00%)Nov 14, 2024
- New$1.8MSep 16, 2024
- New$843.7KAug 14, 2024
- $1MMay 15, 2024
- $225.7KMay 15, 2024
Frequently asked questions
- How many institutional investors hold ALXO?
- 2 tracked institutional investors disclosed a position in ALXO (ALX ONCOLOGY HLDGS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ALXO?
- Izzy Englander, Millennium Management, holds the largest disclosed position in ALXO, valued at $9M.
- Did institutional ownership of ALXO increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 5 increased, 9 reduced, and 4 fully exited ALXO.
- Where does this ALXO ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.